Literature DB >> 20091610

Interventions for preventing infectious complications in haemodialysis patients with central venous catheters.

Margaret McCann1, Zena Eh Moore.   

Abstract

BACKGROUND: Central venous catheters (CVC) continue to play a prominent role in haemodialysis vascular access with 46% to 70% of patients commencing haemodialysis via a CVC. CVC access is associated with catheter-related infections, increased patient hospitalisations and death due to infection. A variety of interventions are used to prevent CVC infection.
OBJECTIVES: To evaluate the benefits and harms of prophylactic topical antimicrobials, topical antiseptics, medicated and non-medicated dressings on infectious complications among haemodialysis patients with CVC. SEARCH STRATEGY: We searched the Cochrane Renal Group's specialised register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and reference lists of articles without language restriction. SELECTION CRITERIA: We included randomised controlled trials (RCTs) and quasi-RCTs investigating any intervention that prevented infectious complications among haemodialysis patients with CVC. We excluded antimicrobial impregnated CVC or CVC using locking solutions with antimicrobial properties. DATA COLLECTION AND ANALYSIS: Two authors assessed study quality and extracted data. Dichotomous outcomes were expressed as risk ratios (RR) with 95% confidence intervals (CI) and continuous outcomes as mean differences (MD). MAIN
RESULTS: Ten studies (786 patients) were included. Mupirocin ointment reduced the risk of catheter-related bacteraemia (RR 0.17, 95%CI 0.07 to 0.43) and had a significant effect on catheter-related infections caused by S. aureus. The risk of catheter-related bacteraemia was reduced by polysporin (RR 0.40, 95%CI 0.19 to 0.86) and povidone-iodine ointment (RR 0.10, 95%CI 0.01 to 0.72). Subgroup analysis suggested mupirocin (RR 0.12, 95%CI 0.01 to 2.13) and povidone-iodine ointment (RR 0.84, 95%CI 0.24 to 2.98) had no effect on all-cause mortality while polysporin ointment showed a significant reduction (RR 0.22, 95%CI 0.07 to 0.74). Mortality related to infection was not reduced by mupirocin, polysporin or povidone-iodine ointment. Topical honey did not reduce the risk of exit site infection (RR 0.45, 95%CI 0.10 to 2.11) or catheter-related bacteraemia (RR 0.80, 95%CI 0.37 to 1.73). Transparent polyurethane dressing compared to dry gauze dressing did not reduce the risk of CVC or exit site infection, or catheter-related bacteraemia. AUTHORS'
CONCLUSIONS: Mupirocin ointment appears effective in reducing the risk of catheter-related bacteraemia. Insufficient reporting on mupirocin resistance was noted and needs to be considered in future studies. A lack of high quality data on the routine use of povidone-iodine ointment, polysporin ointment and topical honey warrant larger RCTs. Insufficient data were available to determine which dressing type (transparent polyurethane or dry gauze dressing) has the lowest risk of catheter-related infections.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20091610     DOI: 10.1002/14651858.CD006894.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  20 in total

1.  A novel chimeric lysin shows superiority to mupirocin for skin decolonization of methicillin-resistant and -sensitive Staphylococcus aureus strains.

Authors:  Mina Pastagia; Chad Euler; Peter Chahales; Judilyn Fuentes-Duculan; James G Krueger; Vincent A Fischetti
Journal:  Antimicrob Agents Chemother       Date:  2010-11-22       Impact factor: 5.191

2.  A Cautionary Tale on the Central Venous Catheter: Medical Note for Oral Physicians.

Authors:  Ramasamy Chidambaram
Journal:  Malays J Med Sci       Date:  2015-09

Review 3.  Infectious complications in dialysis--epidemiology and outcomes.

Authors:  Philip Kam-Tao Li; Kai Ming Chow
Journal:  Nat Rev Nephrol       Date:  2011-12-20       Impact factor: 28.314

Review 4.  Prevention of catheter-related bloodstream infection in patients on hemodialysis.

Authors:  Michiel G H Betjes
Journal:  Nat Rev Nephrol       Date:  2011-03-22       Impact factor: 28.314

5.  REDUcing the burden of dialysis Catheter ComplicaTIOns: a National approach (REDUCCTION) - design and baseline results.

Authors:  Sradha Kotwal; Sarah Coggan; Stephen McDonald; Girish Talaulikar; Alan Cass; Stephen Jan; Kevan R Polkinghorne; Nicholas A Gray; Martin Gallagher
Journal:  Kidney360       Date:  2020-06-02

6.  Neomycin Sulfate Improves the Antimicrobial Activity of Mupirocin-Based Antibacterial Ointments.

Authors:  Catlyn Blanchard; Lauren Brooks; Andrew Beckley; Jennifer Colquhoun; Stephen Dewhurst; Paul M Dunman
Journal:  Antimicrob Agents Chemother       Date:  2015-11-23       Impact factor: 5.191

Review 7.  Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end-stage kidney disease.

Authors:  Ying Wang; Jessica N Ivany; Vlado Perkovic; Martin P Gallagher; Mark Woodward; Meg J Jardine
Journal:  Cochrane Database Syst Rev       Date:  2016-04-04

8.  Effect of the application of a bundle of three measures (intraperitoneal lavage with antibiotic solution, fascial closure with Triclosan-coated sutures and Mupirocin ointment application on the skin staples) on the surgical site infection after elective laparoscopic colorectal cancer surgery.

Authors:  Jaime Ruiz-Tovar; Carolina Llavero; Vicente Morales; Carlos Gamallo
Journal:  Surg Endosc       Date:  2018-01-18       Impact factor: 4.584

Review 9.  Skin antisepsis for reducing central venous catheter-related infections.

Authors:  Nai Ming Lai; Nai An Lai; Elizabeth O'Riordan; Nathorn Chaiyakunapruk; Jacqueline E Taylor; Kenneth Tan
Journal:  Cochrane Database Syst Rev       Date:  2016-07-13

Review 10.  Catheter impregnation, coating or bonding for reducing central venous catheter-related infections in adults.

Authors:  Nai Ming Lai; Nathorn Chaiyakunapruk; Nai An Lai; Elizabeth O'Riordan; Wilson Shu Cheng Pau; Sanjay Saint
Journal:  Cochrane Database Syst Rev       Date:  2016-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.